Histogenics Corp
-
Financial
Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) — ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA…
Read More » -
Financial
Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants
WALTHAM, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Biologics
Histogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee
WALTHAM, Mass., July 23, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Financial
Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results
WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Biologics
Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors
WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Financial
Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017
WALTHAM, Mass., March 15, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Biologics
Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Financial
Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Biologics
Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese NeoCart Agreement
WALTHAM, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Biologics
Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market
WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Financial
Zacks Investment Research Downgrades Histogenics Corp (HSGX) to Sell
Histogenics Corp (NASDAQ:HSGX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, AnalystRatings.NET reports.…
Read More » -
Financial
Analysts Give Average Recommendation of “Buy” to Histogenics Corp (NASDAQ:HSGX)
By John Miller Shares of Histogenics Corp (NASDAQ:HSGX) have been given a consensus broker rating score of 1.50 (Buy) from…
Read More » -
Financial
Histogenics Corp Given a $13.00 Price Target at BTIG Research (HSGX)
By Doug Madison BTIG Research set a $13.00 price objective on Histogenics Corp (NASDAQ:HSGX) in a research report released on…
Read More »